Independent evolution of the env and pol genes of HIV-1 during zidovudine therapy

AIDS

Volumn 10, Issue 10, 1996, Pages 1067-1073

  Leigh Brown, Andrew J ^a   Cleland, Alexander ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Antiviral resistance; Genetic variation; Phylogenetic analysis; Recombination; Zidovudine

Indexed keywords

ANTIVIRUS AGENT; ZIDOVUDINE;

ARTICLE; CASE REPORT; ENVELOPE GENE; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MONONUCLEAR CELL; NUCLEOTIDE SEQUENCE; PHYLOGENY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; STRUCTURAL GENE; VIRUS GENE;

AMINO ACID SEQUENCE; ANTI-HIV AGENTS; CODON; DRUG RESISTANCE, MICROBIAL; GENES, ENV; GENES, POL; HIV INFECTIONS; HIV-1; HUMANS; LIKELIHOOD FUNCTIONS; MOLECULAR SEQUENCE DATA; MUTAGENESIS; PHYLOGENY; POLYMERASE CHAIN REACTION; PROVIRUSES; RECOMBINATION, GENETIC; SEQUENCE ANALYSIS, DNA; TIME FACTORS; VARIATION (GENETICS); ZIDOVUDINE;

EID: 0004732998     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Boucher CA, O'Sullivan E, Mulder JW, et al.: Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. J Infect Dis 1992, 165:105-110.
2. Larder BA, Darby C, Richman DD: HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989, 243:1731-1734.
3. Kellam P, Boucher CA, Tijnagel IM, Larder BA: Zidovudine treatment results in the selection of human immunodeficiency virus type 1 variants whose genotypes confer increasing levels of drug resistance. J Gen Virol 1994, 75:341-351.
4. Boucher CAB, Tersmette M, Lange JMA, et al.: Zidovudine sensitivity of human immunodeficiency viruses from high-risk, symptom-free individuals during therapy. Lancet 1990, 336:585-590.
5. Loveday C, Kaye S, Tenant-Flowers M, Semple M, Weller IVD, Tedder RS: HIV-1 RNA serum-load and resistant viral genotypes during early zidovudine therapy. Lancet 1995, 345:820-824.
6. Wei X, Ghosh SK, Taylor ME, et al.: Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995, 373:117-122.
7. St Clair MH, Martin JL, Tudor Williams C, et al.: Resistance to ddl and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 1991, 253:1557-1559.
8. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M: Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995, 373:123-126.
9. Larder BA, Kemp SD: Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 1989, 246:1155-1158.
10. Kellam P, Boucher CA, Larder BA: Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc Natl Acad Sci USA 1992, 89:1934-1938.
11. Cleland A, Watson HG, Robertson P, Ludlam CA, Leigh Brown AJ: Evolution of zidovudine resistance-associated genotypes in human immunodeficiency virus type 1-infected patients. J Acquir Immune Defic Syndr 1996, 12:6-18.
12. Kishino H, Hasegawa M: Evaluation of the maximum likelihood estimate of the evolutionary tree topologies from DNA sequence data and the branching order in Hominoidea. J Mol Evol 1989, 4:406-425.
13. Ludlam CA, Tucker J, Steel CM, et al.: Human T-lymphotropic virus type III (HTLV-III) infection in seronegative haemophiliacs after transfusion of factor VIII. Lancet 1985, ii:233-236.
14. Myers G, Korber B, Hahn BH, et al.: Human Retroviruses and AIDS 1995. Los Alamos: Los Alamos National Laboratory; 1995.
15. Leigh Brown AJ, Simmonds P: Sequence analysis of virus variability based on PCR. In HIV: A Practical Approach; Volume 1, Virology and Immunology. Edited by Karn J. Oxford: Oxford University Press; 1995:161-188.
16. Felsenstein J: PHYLIP - phylogeny inference package (version 3.2). Cladistics 1989, 5:164-166.
17. Kumar S, Tamura K, Nei M: MEGA: Molecular Evolutionary Genetics Analysis, Version 1.01. University Park: Pennsylvania State University; 1993.
18. Fouchier RA, Groenink M, Kootstra NA, et al.: Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J Virol 1992, 66:3183-3187.
19. Milich L, Margolin B, Swanstrom R: V3 loop of the human immunodeficiency virus type 1 env protein: interpreting sequence variability. J Virol 1993, 67:5623-5634.
20. Simmonds P, Zhang LQ, McOmish F, Balfe P, Ludlam CA, Leigh Brown AJ: Discontinuous sequence change of human immunodeficiency virus (HIV) type 1 env sequences in plasma viral and lymphocyte-associated proviral populations in vivo: implications for models of HIV pathogenesis. J Virol 1991, 65:6266-6276.
21. Holmes EC, Zhang LQ, Simmonds P, Ludlam CA, Leigh Brown AJ: Convergent and divergent sequence evolution in the surface envelope glycoprotein of human immunodeficiency virus type 1 within a single infected patient. Proc Natl Acad Sci USA 1992, 89:4835-4839.
22. Wolfs TFW, de Jong JJ, Van den Berg H, Tijnagel JM, Krone WJ, Goudsmit J: Evolution of sequences encoding the principal neutralization epitope of human immunodeficiency virus 1 is host dependent, rapid, and continuous. Proc Natl Acad Sci USA 1990, 87:9938-9942.
23. Wolfs TFW, Zwart G, Bakker M, Goudsmit J: HIV-1 genomic RNA diversification following sexual and parenteral virus transmission. Virology 1992, 189:103-110.
24. Sheehy N, Desselberger U, Whitwell H, Ball JK: Concurrent evolution of regions of the envelope and polymerase genes of human immunodeficiency virus type 1 observed during zidovudine (AZT) therapy. J Gen Virol 1996, 76:1071-1081.
25. Potts KE, Kalish ML, Lott T, et al.: Genetic heterogeneity of the V3 region of the HIV-1 envelope glycoprotein in Brazil. AIDS 1993, 7:1191-1197.
26. Zhu T, Wang N, Carr R, Wolinsky SM, Ho DD: Evidence for coinfection by multiple strains of human immunodeficiency virus type 1 subtype B in an acute seroconvertor. J Virol 1995, 69:1324-1327.
27. Diaz RS, Sabino EC, Mayer A, Mosley JW, Busch MP, Transfusion Safety Study Group: Dual human immunodeficiency virus type 1 infection and recombination in a dually exposed transfusion recipient. J Virol 1995, 69:3273-3281.
28. Robertson DL, Sharp PM, McCutchan FE, Hahn BH: Recombination in HIV-1. Nature 1995, 374:124-126.
29. Tisdale M, Myers RE, Maschera B, Parry NR, Oliver NM, Blair ED: Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors. Antimicrob Agents Chemother 1995, 39:1704-1710.
30. Collier AC, Coombs RW, Schoenfeld DA, et al.: Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. N Engl J Med 1996, 334:1011-1017.
31. Eron JJ, Benoit SL, Jemsek J, et al.: Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party. N Engl J Med 1995, 333:1662-1669.
32. Larder BA, Kemp SD, Harrigan PR: Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 1995, 269:696-699.
33. Zhang LQ, MacKenzie P, Cleland A, Holmes EC, Leigh Brown AJ, Simmonds P: Selection for specific sequences in the external envelope protein of human immunodeficiency virus type 1 upon primary infection. J Virol 1993, 67:3345-3356.